All In Biotech

Drug Trial Radar · NCT00268216

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment

Last checked: Nov 19, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,228

Actual

Start

Sep 2000

Primary completion

Nov 2005

Study completion Nov 2005

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Salmeterol 50mcg/ Fluticasone Propionate 500mcgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All cause mortality at 3 years

Locations

459 sites in 44 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Jasper, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Ozark, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Berkeley, California

  • GSK Investigational Site

    Burbank, California

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Fullerton, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Rancho Mirage, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Luis Obispo, California

  • GSK Investigational Site

    Sepuldeva, California

  • GSK Investigational Site

    Stockton, California

  • GSK Investigational Site

    Sunnyvale, California

  • GSK Investigational Site

    Sylmar, California

  • GSK Investigational Site

    Vista, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Arvada, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Fort Collins, Colorado

  • GSK Investigational Site

    Longmont, Colorado

  • GSK Investigational Site

    Loveland, Colorado

  • GSK Investigational Site

    Pueblo, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

Showing 40 of 459 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.